Trial Profile

An Open Label, Phase 2 Study to Evaluate Activity and Safety of Daratumumab in Combination With Bortezomib and Dexamethasone in Patients With Relapsed or Refractory Plasmablastic Lymphoma (DALYA Trial)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 29 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bortezomib (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary)
Indications Plasmablastic lymphoma
Focus Therapeutic Use
Acronyms DALYA Trial

16 Jul 2025 Planned End Date changed from 1 Jan 2025 to 1 Jan 2026.
16 Jul 2025 Planned primary completion date changed from 1 Jan 2025 to 1 Jan 2026.
20 Dec 2024 Planned End Date changed from 1 Jun 2024 to 1 Jan 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com